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Key Points
• RA synergizes with the
N-glycosylation inhibi-
tor tunicamycin and
ATO to induce AML cell
death via generation of
ER and oxidative stress.
Acute myeloid leukemia (AML) is often characterized by the expression of fusion or mutant
proteins that cause impaired differentiation and enhanced proliferation and survival. The
presenceofmutant proteins prone tomisfolding can render the cells sensitive to endoplasmic
reticulum (ER) stress and oxidative stress that could otherwise be overcome. Here, we show
that the triple combination of the differentiating agent retinoic acid (RA), the ER
stress–inducing drug tunicamycin (Tm), and arsenic trioxide (ATO), able to generate
oxidative stress, leads to the death of AML cell lines expressing fusion proteins involving the
gene MLL and the internal tandem duplication (ITD) in the FLT3 tyrosine kinase receptor.
Importantly, the combination of RA, Tm, and ATO decreased the colony-forming capacity of
primary leukemic blasts bearing the FLT-ITD mutation without affecting healthy
hematopoietic progenitor cells. We demonstrate in cell lines that combination of these drugs
generates ER and oxidative stresses and impairs maturation and causes accumulation of
FLT3 protein in the ER. Our data provide a proof of concept that low amounts of drugs that
generate ER and oxidative stresses combined with RA could be an effective targeted therapy
to hit AML cells characterized by MLL fusion proteins and FLT3-ITD mutation.
Introduction
Present therapies for acute myeloid leukemia (AML) provide a rate of cure of 40% to 50%; therefore,
novel approaches are needed.1 Endoplasmic reticulum (ER) stress triggers the unfolded protein
response (UPR), which plays an essential role in maintaining protein homeostasis (proteostasis). The
concept of perturbing proteostasis to promote cancerous cell death has been extensively described in
multiple myeloma.2 We demonstrated that the ER stress–inducing drug tunicamycin (Tm) led to acute
promyelocytic leukemia cell death in synergy with the differentiation agent retinoic acid (RA) and arsenic
trioxide (ATO), which generates oxidative stress,3 at low doses of each drug, which had little or no effect
when used alone. Furthermore, the acute promyelocytic leukemia oncogenic fusion protein PML-RARa
formed intracellular protein aggregates upon treatment with RA and Tm, further exacerbating stress of
the secretory protein folding compartment. Thus, mutant proteins, characterizing a variety of AMLs,
could provide the basis of high sensitivity to drug-induced disruption of proteostasis, because they are
often a source of proteostasis imbalance. For example, the mixed lineage leukemia (MLL) protein is
a histone methyltransferase found with .60 fusion partners generating various types of leukemia.4 In
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Figure 1. Combination of ER and oxidative stress with RA induces AML cell death and intracellular accumulation of immature FLT3. (A) ML-2 and MV-4-11
cells, treated for 72 hours with 10 nM RA (R), 50 ng/mL of Tm (T), and 500 nM ATO (A) alone or in combination, were analyzed for propidium iodide (PI) uptake to evaluate
cell death (n 5 16 6 standard error of the mean [SEM]). One-way ANOVA vs C (control, vehicle-treated cells): **P , .005, ***P , .001, ****P , .0001. Student t test
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particular, the MLL-AF6 fusion protein sequesters AF6 into the
nucleus from its normal cytosolic localization.5 The internal tandem
duplication in FMS-like tyrosine kinase 3 (FLT3-ITD) is one of the
most common mutations in AML, found in ;30% of patients, and
associated with a poor outcome.6 FLT3-ITD is particularly in-
teresting in this context, because it is a misfolded protein mostly
retained in the ER.7 In this work, we set out to explore the sensitivity
of AML cells expressing different oncogenic proteins to the
combination of low doses of RA, Tm, and ATO (RTA).
Methods
Cell culture
ML-2, MV-4-11, MOLM13, THP1, SKNO-1, HL60, HEL, U937,
OCI-AML-2, and OCI-AML-3 cell lines were treated with 10 nM
RA, 50 ng/mL of Tm, 500 nM ATO, 20 mM N-acetylcysteine (NAC),
and 2.5 mM 4-PBA alone or in combination, as indicated in figures
for each experiment. Primary cells isolated from bone marrow were
cultured in Methocult 4035 medium with or without 10 nM RA,
50 ng/mL of Tm, and 500 nM ATO alone or in combination.
Cell death and differentiation
Cell death was evaluated by propidium iodide exclusion assay.
Cell differentiation of AML primary blasts and healthy bone
marrow cells, grown in Methocult medium for 8 days, was assessed
by morphological analysis of cytospin preparations stained with
Wright-Giemsa.
Immunofluorescence
Confocal microscopy was performed on cytospin preparations
stained with primary anti-FLT3 and anti-BiP antibodies followed by
anti-rabbit Alexa Fluor-488 or anti-mouse Alexa Fluor-555. DNA was
counterstained with TOPRO-3. The images were acquired with the
Leica laser scanning microscope TCS SP2 using the 403 objective.
Quantitative real-time polymerase chain reaction
Quantitative real-time polymerase chain reaction was analyzed by
the DDCt method using histone 3 or glyceraldehyde-3-phosphate
dehydrogenase as endogenous control for standardization.
Western blot
Total protein extract (20-40 mg) was separated by SDS–PAGE, in
reducing or nonreducing conditions.
Detailed materials and methods are available in the supplemental
Material.
Results and discussion
Among a panel of AML cells carrying different oncogenic mutant
proteins, the ML-2, MOLM-13, and MV-4-11 cells, expressing the
fusion proteins MLL-AF6, MLL-AF9 plus FLT3-ITD, and MLL-AF4
plus FLT3-ITD, respectively, were the most sensitive to the RTA
combination; sensitivity was more significant in the ML-2 and
MV-4-11 cells (Figure 1A; supplemental Figure 1A; supplemental
Table 1). It is worth noticing that the pair comprising THP1 and
ML-2, expressing MLL fusion proteins, and the pair comprising
MOLM-13 and MV-4-11, expressing MLL fusion proteins and
FLT3-ITD, showed similar patterns of response to the different
treatments. ML-2 and MV-4-11 cells exhibited a diverse sensitivity
to RA that was not surprising, considering the wide range of
responses to RA of different types of AML described in literature.8
When we treated primary leukemic cells with the same drugs,
we found that the RTA combination significantly impaired the
clonogenic capacity of primary cells harvested from the bone
marrow of FLT3-ITD1 AML patients, and morphological analysis
revealed that a high percentage of RTA-treated cells presented
nuclear vacuoles, suggesting cell death (Figure 1B upper panel;
Figure 1C). However, the same combination had no significant
effect on leukemic blasts negative for the FLT3-ITD mutation
(Figure 1B middle panel). Although these analyses must be
extended to a higher number of samples, they suggest that AML
primary FLT3-ITD1 cells are sensitive to the RTA combination,
independently of the presence of additional mutations (supplemen-
tal Table 2). Importantly, the effects of RTA were specific to
leukemic cells, because the same combination did not alter the
clonogenic capacity of hematopoietic progenitor cells isolated
from the bone marrow of healthy donors (Figure 1B lower panel;
supplemental Figure 1).
We then investigated the stress responses activated by RTA. It is
established that the ITD of FLT3 impairs its full glycosylation and
folding, causing its retention in the ER.7 Accordingly, we observed
that FLT3-ITD is partially retained in the ER in an immature form and
that treatment with RTA caused further hindrance of protein
maturation and retention in the ER of FLT3-ITD in MV-4-11 cells, as
well as of wild-type FLT3 in ML-2 cells (Figure 1D-E). Instead, Tm
alone increased the ratio between underglycosylated and mature
FLT3-ITD only slightly (supplemental Figure 2), suggesting that only
Figure 1. (continued) ####P , .0001. Synergy of RA, Tm, and ATO was confirmed by the Chou-Talalay method21 (combination index in MV-4-11 cells, 0.34). (B) Colony-
forming unit assay for AML blasts isolated from the bone marrow (BM) of 6 patients who were FLT3-ITD1 and 3 who were FLT-ITD2 and for mononucleated cells isolated from
4 healthy donors. The cells were treated in semisolid medium with 10 nM RA, 50 ng/mL of Tm, and 500 nM ATO alone or in combination as indicated. After 8 days, the colony
size (number of cells per colony) was evaluated by microscopy. The graphs report the ratio of the average number of cells forming the colonies of each treated sample over its
control. Student t test ***P , .001. (C) Morphological analysis of AML1 cells isolated from 8-day colonies obtained in panel B. Black arrows indicate cell vacuoles. The graph
at the bottom reports the average ratio of the number of vacuolated cells over those nonvacuolated (n 5 3 6 SEM). One-way ANOVA vs C: *P , .05, ***P , .001. Student
t test of TA vs RTA: †P, .05. (D) Western blot of ML-2 and MV-4-11 protein extracts from cells treated with vehicle, C, or with the combination RTA, as in panel A, for
48 hours to detect FLT3. Control ML-2 cells had no detectable levels of FLT3; FLT3 was instead accumulated in immature, not fully glycosylated forms upon treatment with
RTA. MV-4-11 cells carry a homozygous FLT3-ITD mutation that is mostly retained intracellularly in immature forms (C). Treatment of cells with RTA further impaired FLT3-ITD
glycosylation, as demonstrated by the disappearance of the fully glycosylated (mature) form and by the increase of the less glycosylated form. (E) Confocal analysis of the
distribution of FLT3 and BiP proteins in ML-2 and MV-4-11 cells in control and RTA-treated cells. According to the observations obtained by western blot analysis in panel A,
FLT3 is found on the plasma membrane of ML-2 control cells and accumulates in the ER upon treatment with RTA. BiP is the main ER chaperone, and colocalization of FLT3
with BiP demonstrates misfolding and retention in the ER (yellow spots in inset 1). FLT3-ITD is already retained intracellularly in control MV-4-11 cells, and treatment with RTA
increases the amount of FLT3-ITD in the ER (inset 2). ns, not significant.
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Figure 2. Treatment of ML-2 and MV-4-11 cells with the RTA combination triggers the UPR and the oxidative stress response. (A) The RNA of ML-2 and
MV-4-11 cells, treated as described in Figure 1A for 24 or 72 hours, was analyzed by quantitative real-time polymerase chain reaction for the expression of UPR target genes (the
transcription factor CHOP, the ER chaperone BiP, and the spliced, active form of the transcription factor XBP1 [sXBP1]) and for the expression of HMOX, a gene with a main role in the
oxidative stress response. sXBP1 induces the expression of a plethora of genes that increase the ER folding capacity, whereas CHOP is involved in the proapoptotic
branch of the UPR (ML-2, n 5 5 6 SEM; MV-4-11, n 5 3 6 SEM; ML-2 and MV-4-11 HMOX, n 5 2 6 SEM). Student t test vs C: *P , .05, **P , .005, ***P , .001.
Student t test vs RA: †P , .05, ††P , .005, †††P , .001. (B) Western blot of ML-2 and MV-4-11 protein extracts, from cells treated as in panel A for 24 or 72 hours,
to detect CHOP and BiP proteins. The graphs below each western blot report densitometric quantification (n 5 2 6 SEM). Student t test *P , .05. (C) Confocal analysis
of the expression of the ER chaperone BiP in ML-2 and MV-4-11 cells vehicle or RTA treated. (D) Western blot of protein extracts from ML-2 and MV-4-11 cells vehicle or
RTA treated for 72 hours to detect the complexes among the chaperone BiP and its client misfolded proteins. The 72-KDa BiP monomer is indicated by the arrow.
Unbalance of ER proteostasis upon treatment with RTA determined accumulation of misfolded proteins bound by BiP, indicated as BiP complexes. (E) ML-2 cells, treated
for 72 hours as in Figure 1A in the presence or not of 20 mM NAC or of 2.5 mM sodium-4-phenylbutyrate (PBA), were analyzed for propidium iodide (PI) uptake to
evaluate cell death (NAC, n 5 4 6 SEM; PBA, n 5 3 6 SEM). Student t test *P , .05, ****P , .0001. (F) Western blot of protein extracts from ML-2 cells, treated as in
panel A, to detect the BiP misfolded protein complexes. NAC relieved oxidative stress induced by RTA and rescued the functionality of the ER, as indicated by the
reduction of BiP protein level and by the loss of BiP complexes. A similar effect, although in minor measure, was achieved by PBA.
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the RTA combination appreciably affected the folding efficiency of
the ER. Nonetheless, Tm activated the UPR in ML-2 and MV-4-11
cells either alone or in combination with RA and/or ATO
(Figure 2 A-D). Treatment with ATO alone triggered the oxidative
stress response, which reached much higher levels upon admin-
istration of ATO in combination with RA and Tm, as shown by
increased expression of the gene HMOX-1, a main player in this
response (Figure 2A). ER stress and oxidative stress are tightly
linked, even though the mechanisms of interaction between these
stresses are still unknown.9 Indeed, generation of reactive oxygen
species and consequent oxidative stress is one of the mechanisms
triggered by the unfolded protein response to induce apoptosis in
the presence of overwhelming ER stress10; furthermore, altered
redox homeostasis induces ER stress.11 Our data suggest that the
ER stress response triggered by Tm alone and the oxidative stress
response triggered by ATO alone reestablish homeostasis, result-
ing in cell survival, whereas the combination of Tm with ATO and RA
leads to overcoming levels of oxidative stress and consequent cell
death. Indeed, the antioxidant agent NAC rescued the deleterious
effect of the combination of TA and RTA on cell viability of ML-2
cells (Figure 2E) and reduced oxidative and ER stresses (Figure 2F;
supplemental Figure 3). The chemical chaperone sodium-4-phenyl-
butyrate, which favors protein folding,12 produced similar, although
less marked, effects than NAC (Figure 2E-F). The effects of NAC
and sodium-4-phenylbutyrate on MV4-11 cells, treated with RTA,
were comparable to those observed on ML-2 cells, but much milder
(supplemental Figure 4), likely because of the major response to RA
of these cells. Indeed, the molecular mechanisms underlying the
effects of RA on the ER and oxidative stress responses constitute
an open question, which will be important to investigate. Aside from
the differences between the 2 cell lines, our data indicate that
treatment of ML-2 and MV-4-11 cells with RTA activated the UPR
and the oxidative stress response, leading to cell death.
The clinical outcome of FLT3-ITD1 AML and the strong evidence of
the leukemogenic role of mutant FLT3 promoted the development
of tyrosine kinase inhibitors (TKIs).13 Clinical trials with TKIs, both as
monotherapy and in combination with chemotherapy, resulted in
incomplete responses and insurgency of resistance.14,15 Different
strategies to target FLT3-ITD have been explored and are related to
FLT3-ITD structural defects or specific pathways activated by its
aberrant signaling. The proteasome inhibitor bortezomib deter-
mined autophagy-mediated FLT3-ITD degradation and cell death of
FLT3-ITD1 AML cells16; inhibition of FLT3-ITD glycosylation by Tm
caused increased ER stress and cell death and acted in syn-
ergy with a TKI17; pharmacological induction of oxidative stress
enhanced the efficacy of the TKI18; RA synergized with FLT3-TKI to
eliminate leukemia stem cells19; eventually, a combination of RA and
ATO on FLT3-ITD1 AML cell lines inhibited FLT3-ITD signaling,
causing cell death.20 Altogether, these studies indicate the high
interest of the scientific community in identifying a combination of
drugs able to target the leukemogenic mutation FLT3-ITD.
Here, we demonstrate that the RTA combination efficiently
eliminated AML cells with diverse genetic backgrounds, such as
the ML-2 and MV-4-11 cell lines, and primary cells from patients
FLT3-ITD1 disease with different additional mutations. An important
novelty of this work is that in combining RA, Tm, and ATO, we could
use low doses of each drug, which had little or no effect when used
as single agents, maximizing synergy and possibly reducing toxicity.
Although our results need to be further validated in a wider patient
cohort and in in vivo models, they provide a proof of concept that
low amounts of drugs that generate ER and oxidative stresses
combined with RA could be an effective targeted therapy to hit AML
cells characterized by MLL fusion proteins and FLT3-ITD mutation.
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